Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BI 44370 TA Solution vs Tablets
NCT02215746Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2008
- Primary completion
- Apr 2008
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of BI 44370 in migraine (6 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum concentration of the analyte in plasma up to 24 hours, Area under the concentration-time curve 0-2h and 2 more. Started Jan 2008; status: completed.
02
Drugs
BI 44370
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02215746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02215746.